A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases.

Our latest press release

Read more

30/11/2021

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine

Download

To receive OSE Immunotherapeutics’ latest news